DaVita (NYSE:DVA) Updates FY 2024 Earnings Guidance

DaVita (NYSE:DVA) updated its FY 2024 earnings guidance on Friday. The company provided earnings per share guidance of 9.000-9.800 for the period, compared to the consensus earnings per share estimate of 9.010. The company issued revenue guidance of -.

DaVita Stock Performance

Shares of NYSE:DVA traded up $2.42 during trading on Monday, hitting $136.87. 1,433,893 shares of the company were exchanged, compared to its average volume of 846,295. DaVita has a 52-week low of $71.51 and a 52-week high of $145.04. The stock has a 50 day moving average of $133.71 and a 200 day moving average of $113.08. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37. The company has a market cap of $12.00 billion, a PE ratio of 15.49, a P/E/G ratio of 1.17 and a beta of 1.04.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The firm had revenue of $3.07 billion during the quarter, compared to the consensus estimate of $3.03 billion. During the same period last year, the firm earned $1.58 EPS. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. As a group, equities research analysts predict that DaVita will post 9.49 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on DVA shares. UBS Group upped their target price on shares of DaVita from $113.00 to $134.00 and gave the stock a buy rating in a research report on Wednesday, February 14th. Truist Financial upped their target price on DaVita from $130.00 to $135.00 and gave the stock a hold rating in a research note on Tuesday, February 20th. StockNews.com upgraded shares of DaVita from a buy rating to a strong-buy rating in a report on Thursday, April 25th. TheStreet upgraded shares of DaVita from a c+ rating to a b- rating in a research report on Wednesday, February 7th. Finally, Barclays upped their price target on shares of DaVita from $133.00 to $150.00 and gave the company an equal weight rating in a research report on Monday. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, DaVita currently has an average rating of Moderate Buy and a consensus target price of $121.33.

Insiders Place Their Bets

In other DaVita news, insider James O. Hearty sold 26,164 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the transaction, the insider now owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider James O. Hearty sold 26,164 shares of DaVita stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the sale, the insider now owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the transaction, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The disclosure for this sale can be found here. Insiders have sold a total of 134,540 shares of company stock valued at $16,551,071 in the last quarter. Insiders own 1.40% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.